AI-drug-discovery platform bet with one program near a registrational inflection, contingent on FDA defining an approvable path from single-arm Phase 2 data

Recursion is a clinical-stage drug-discovery company using artificial intelligence to develop treatments, with its lead program—a targeted cancer drug for familial adenomatous polyposis—not yet approved but approaching a regulatory decision point on whether single-arm Phase 2 data will suffice for FDA authorization.

Recursion's FAP program, REC-4881, produced a 75% polyp reduction response rate and durable off-treatment effect in a small Phase 2 cohort, prompting FDA pre-registration talks under Fast Track and Orphan designations. The thesis resolves on whether FDA accepts that single-arm, endoscopic-endpoint dataset as the basis for approval, or demands a controlled registrational study that extends timelines well past current cash. A $546M balance sheet covers runway only to early 2028, creating a financing dependency if the registration path proves longer than anticipated.